Ignite Creation Date:
2025-12-24 @ 3:30 PM
Ignite Modification Date:
2025-12-27 @ 9:20 AM
Study NCT ID:
NCT01142492
Status:
COMPLETED
Last Update Posted:
2014-03-18
First Post:
2010-06-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
IMP28157
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Dr. Norbert Zessack/Head of Medicine BU Neurology
Old Organization:
Merck Serono GmbH Germany, an affiliate of MerckKGaA, Darmstadt, Germany